Tiratricol

DRUG5 trials

Sponsors

Rare Thyroid Therapeutics International AB

Conditions

Allan-Herndon-Dudley SyndromeMonocarboxylate Transporter 8 (MCT8) deficiencyMonocarboxylate Transporter 8 Deficiency

Phase 2

Triac Trial II in MCT8 Deficiency Patients

Active, not recruitingNCT02396459

Rare Thyroid Therapeutics International ABAllan-Herndon-Dudley Syndrome

Start: 2020-12-07End: 2027-08-18Updated: 2026-02-20

Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II (MCT8-2019-2)

Active, not recruitingCTIS2024-516123-13-00

Rare Thyroid Therapeutics International ABMonocarboxylate Transporter 8 (MCT8) deficiency

Start: 2021-02-03Target: 13Updated: 2025-06-06

Phase 3

Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)

CompletedNCT05579327

Rare Thyroid Therapeutics International ABAllan-Herndon-Dudley Syndrome, Monocarboxylate Transporter 8 Deficiency

Start: 2023-07-21End: 2025-09-03Updated: 2026-04-08

Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Doubleblind, Randomized, Placebocontrolled Study (MCT8-2021-3 (ReTRIACt))

CompletedCTIS2024-516124-34-00

Rare Thyroid Therapeutics International ABMonocarboxylate Transporter 8 (MCT8) deficiency

Start: 2023-07-21End: 2025-09-03Target: 5Updated: 2025-12-12

Unknown Phase

Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency

Rare Thyroid Therapeutics International ABAllan-Herndon-Dudley Syndrome, Monocarboxylate Transporter 8 Deficiency

Updated: 2026-05-05

Related Papers

Diagnosis and Therapy in MCT8 Deficiency: Ongoing Challenges

Journal of Clinical Research in Pediatric Endocrinology2024-02-122 citations

Oligodendroglial Lineage Cells in Thyroid Hormone-Deprived Conditions.

2019-04-3013 citations